DEINOVE news, videos and press releases
For more news please use our advanced search feature.
DEINOVE - More news...
DEINOVE - More news...
- Conversion of the receivership proceedings into judicial liquidation proceedings
- Deinove Announces the Opening of Receivership Proceedings
- DEINOVE REQUESTS RECEIVERSHIP PROCEEDINGS
- DEINOVE - Adoption of the resolutions at the Shareholders’ Extraordinary General Meeting on October 17, 2022
- DEINOVE - Adoption of all the ordinary resolutions at the Shareholders’ Meeting of May 30, 2022
- DEINOVE presents its financial results and the advancement of its programs for 2021
- Michael MOUREZ joins the DEINOVE team as Chief Innovation Officer
- DEINOVE announces a favorable opinion from the DSMB for the continuation of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections
- The ATB-Discover project, led by DEINOVE, IBMM and the LMP of the University of Montpellier, is supported by the European Union and Occitania Region
- DEINOVE- Adoption of all the ordinary resolutions at the Shareholders’ Meeting of June 21, 2021
- DEINOVE- Second convening to a Combined General Meeting on June 21, 2021
- DEINOVE, ESPCI Paris and INRAE awarded grant following the call for proposals of the French “Antibiotic resistance” Priority Research Program
- DEINOVE presents its financial results and the advancement of its programs for 2020
- Issuance of a 5th tranche of 3 millions EUR of notes convertible into new shares
- Issuance of a 4th tranche of €1.5 million of notes convertible into new shares
- DEINOVE signs an Evaluation and Technology Development License with DSM
- DEINOVE selected for a presentation at the C Diff Foundation annual Conference 2020
- DEINOVE Selected for a Presentation at the C Diff Foundation Annual Conference 2020
- DEINOVE: 2020 Half-year Results: Stronger Financial Position and Research Programs Moving Forward Despite the International Context
- 2020 Half-year results: Stronger financial position and research programs moving forward despite the international context
- DEINOVE: DNV3837 Antibiotic Candidate: the Phase II Trial Continues in the United States, Despite a Disrupted Context Due to The COVID-19 Outbreak
- DNV3837 antibiotic candidate: the Phase II trial continues in the US
- DEINOVE: Issuance of a 3rd Tranche of €1.5 Million of Notes Convertible Into New Shares
- Alexis RIDEAU appointed Chief Executive Officer of DEINOVE with the ambition to strengthen the Company's strategy for innovation and partnerships
- Alexis RIDEAU Appointed Chief Executive Officer of DEINOVE With the Ambition to Strengthen the Company's Strategy for Innovation and Partnerships
- DEINOVE: 2019 Annual Results: a Year of Important Milestones in Both Antibiotics and Cosmetics Activities
- Official launch of Luminity®, DEINOVE's new cosmetic active ingredient for a radiant complexion
- Official Launch of Luminity®, DEINOVE's New Cosmetic Active Ingredient for a Radiant Complexion
- DEINOVE: Issuance of a 2nd Tranch of €1 Million of Notes Convertible Into New Shares
- DEINOVE Obtains From Société Générale Factoring the Pre-funding Of Its 2019 R&D Tax Credit Receivable Amounting to EUR 2.1 Million
